Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 3,447 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neoplasms,Colorectal Clear all
Completed Not applicable Interventional

Treatment for Persistently Fatigued Cancer Survivors: A Randomized Controlled Trial With Biomarker Response

NCT01919853
View directory record Official record
Conditions
Fatigue
Interventions
Mindfulness-Based Stress Reduction, Attention Control
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 28, 2026, 3:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Colorectal Polyp Resection Adequacy

NCT02217085
View directory record Official record
Conditions
Polyp Resection Adequacy
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 28, 2026, 3:42 AM EDT
Recruiting Not applicable Interventional

The Food Environment, Microbial Cysteine Metabolism, and Cancer Disparities

NCT07086833
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Low Cysteine Diet, High Cysteine Diet
Other
Lead sponsor
Purdue University
Other
Eligibility
45 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Indianapolis, Indiana • West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

NCT04456699
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Olaparib, 5-FU, Bevacizumab, Capecitabine, Leucovorin/ levoleucovorin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Burbank, California • Fullerton, California • Colorado Springs, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 28, 2026, 3:42 AM EDT
Not listed No phase listed Observational

TRIAD Burden of Illness Mucositis Study

NCT00336609
View directory record Official record
Conditions
Gastrointestinal Mucositis (Defined as Mucositis Involving the Mouth, Esophagus, or Small Intestine)
Interventions
Not listed
Lead sponsor
TRIAD Burden of Illness
Other
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 20, 2007 · Synced Oct 28, 2026, 3:42 AM EDT
Withdrawn Phase 1 Interventional

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

NCT04500548
View directory record Official record
Conditions
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Primary Central Nervous System Neoplasm, Xeroderma Pigmentosum
Interventions
Biospecimen Collection, Ipilimumab, Nivolumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Palo Alto, California • Aurora, Colorado • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 28, 2026, 3:42 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer

NCT00601198
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Amifostine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 28, 2026, 3:42 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

NCT02817633
View directory record Official record
Conditions
Neoplasms
Interventions
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
64
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 28, 2026, 3:42 AM EDT
Recruiting Not applicable Interventional

Colonoscopy vs Stool Testing for Older Adults With Colon Polyps

NCT05612347
View directory record Official record
Conditions
Colorectal Polyp, Colorectal Neoplasms, Colorectal Adenoma, Colorectal Cancer, Digestive System Disease
Interventions
FIT, Colonoscopy
Diagnostic Test
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
65 Years to 82 Years
Enrollment
6,434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Not applicable Interventional Results available

Project HERO: Health Empowerment & Recovery Outcomes

NCT03345563
View directory record Official record
Conditions
Prostate Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Rectum Cancer, Thyroid Cancer, Lung Cancer, Small Intestine Cancer, Soft Tissue Cancer
Interventions
Body Mind Training (BMT), Body Training (BT):, Usual Care (UC)
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
55 Years and older · Male only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 28, 2026, 3:42 AM EDT
Withdrawn Not applicable Interventional

Pancreatic Cancer Screening of High-Risk Individuals in Arkansas

NCT02309632
View directory record Official record
Conditions
Pancreatic Neoplasms, Peutz-Jegher's Syndrome, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ataxia Telangiectasia, Familial Atypical Mole-Malignant Melanoma Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Hereditary Pancreatitis
Interventions
Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 1 Interventional

Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer

NCT00532909
View directory record Official record
Conditions
Anal, Colon, and Rectal Cancers, Colorectal Neoplasms, Colon/Rectal Cancer
Interventions
Vandetanib, Capecitabine, Oxaliplatin, Bevacizumab
Drug
Lead sponsor
Branimir Sikic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 28, 2026, 3:42 AM EDT
Terminated Phase 2 Interventional

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

NCT04952753
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
NIS793, Bevacizumab, Modified FOLFOX6, FOLFIRI, Tislelizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 2 Interventional

A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer

NCT00055419
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Cetuximab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
29
States / cities
Bakersfield, California • Los Angeles, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2010 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Narrow-Band Imaging Versus Standard White Light for the Detection of Serrated Lesions in the Proximal Colon

NCT01572428
View directory record Official record
Conditions
Colon Cancer
Interventions
Inspection with Narrow-Band Imaging(NBI), Standard White Light
Procedure
Lead sponsor
Indiana University
Other
Eligibility
50 Years to 85 Years
Enrollment
898 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 28, 2026, 3:42 AM EDT
Active, not recruiting Not applicable Interventional Results available

Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)

NCT01696981
View directory record Official record
Conditions
Colon Carcinoma, Rectal Carcinoma
Interventions
Screening Questionnaire Administration, Sigmoidoscopy
Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
55 Years to 74 Years
Enrollment
154,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 3:42 AM EDT
Withdrawn Phase 2 Interventional

Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer

NCT02413853
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions
CBP/beta-catenin Antagonist PRI-724, Bevacizumab, Leucovorin Calcium, Oxaliplatin, Fluorouracil, Laboratory Biomarker Analysis
Drug · Biological · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 28, 2026, 3:42 AM EDT
Recruiting Phase 3 Interventional

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

NCT05855200
View directory record Official record
Conditions
Colonic Neoplasms, Neoplasms, Colon
Interventions
Dostarlimab, CAPEOX, FOLFOX
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
49
States / cities
Tucson, Arizona • Los Angeles, California • New Haven, Connecticut + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 28, 2026, 3:42 AM EDT
Terminated Not applicable Interventional

Effect of Use of Straw on Tolerability and Quality of Split Dose 4l-PEG Preparation

NCT02317731
View directory record Official record
Conditions
Colon Cancer
Interventions
Straw
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 28, 2026, 3:42 AM EDT
Recruiting Phase 2 Interventional

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

NCT05705492
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Gastric Carcinoma, Metastatic Colorectal Carcinoma (mCRC), Advanced Lung Carcinoma, Locally Advanced Hepatocellular Carcinoma
Interventions
Olanzapine, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 28, 2026, 3:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Frequency of Endometrial Cancer Precursors Associated with Lynch Syndrome

NCT05257057
View directory record Official record
Conditions
Lynch Syndrome, Endometrial Cancer, Endometrial Hyperplasia, Mismatch Repair Deficiency, Microsatellite Instability
Interventions
Immunohistochemical staining
Diagnostic Test
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 28, 2026, 3:42 AM EDT
Completed Phase 3 Interventional Results available

Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

NCT02135419
View directory record Official record
Conditions
Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection
Interventions
imiquimod, fluorouracil, infrared photocoagulation therapy, thermal ablation therapy, laser therapy, clinical observation, laboratory biomarker analysis
Drug · Device · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
35 Years and older
Enrollment
4,446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
24
States / cities
Los Angeles, California • Palm Springs, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 28, 2026, 3:42 AM EDT
Active, not recruiting Phase 1 Interventional

Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

NCT04046445
View directory record Official record
Conditions
Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer, Metastatic Colorectal Cancer, Liver Metastasis Colon Cancer
Interventions
ATP128, BI 754091, VSV-GP128
Drug
Lead sponsor
Amal Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 28, 2026, 3:42 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

NCT04137107
View directory record Official record
Conditions
Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
Interventions
Oxaliplatin, Duloxetine Hydrochloride, Duloxetine, Quality-of-Life Assessment, Questionnaire Administration, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
792
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 525 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 28, 2026, 3:42 AM EDT